Endothelial function of vessels in patients with chronic kidney disease combined with subclinical hypothyroidism under the influence of combined antihypertensive therapy.
DOI:
https://doi.org/10.26641/2307-0404.2018.3(part1).142333Ключові слова:
chronic kidney disease, arterial hypertension, subclinical hypothyroidism, combined antihypertensive therapy, brachial artery flow-mediated dilationАнотація
The aim of the study: to evaluate the endothelial function of the vessels under the influence of combined antihypertensive therapy (valsartan 160 mg / amlodipine 5 mg vs valsartan 160 mg / hydrochlorothiazide 12,5 mg) in patients with CKD and subclinical hypothyroidism. 80 patients with CKD I-II stages and AH 1 and 2 degrees were examined. According to TSH level patients were divided into 2 groups. Than patients with SH were separated into 2 subgroups: 1a – patients that received valsartan 160mg/ amlodipine 5 mg and 1b - patients that received valsartan 160mg/ hydrochlorothiazide 12,5 mg). More often violation of brachial artery flow-mediated dilation was found among the main group. The use of two-component antihypertensive therapy based on valsartan 160 mg and amlodipine 5 mg or valsartan 160 mg and hydrochlorothiazide 12,5 mg ensured the achievement of target blood pressure levels in 83,3% and 84% of patients, respectively. The more significant improvement of brachial artery flow-mediated dilation was observed in patients that received fixed combination valsartan 160 mg/amlodipine 5 mg.
Посилання
Kuryata OV, Karavanska IL, Frolova EO, Mitrochina OS, Кushnir JS, Garmish IP. [Secondary (symptomatic) arterial hypertension: a teaching manual]. Dnipro, Gerda. 2017;124. Ukrainian.
Kuryata OV, Garmish IP. [The effectiveness of combined antihypertensive therapy in patients with chronic kidney disease combined with subclinical hypothyroidism]. Semeynaya meditsina. 2017;3(71):22-27. Ukrainian.
Kuryata OV, Garmish IP. [Proteinuria level and state of endothelial function of blood vessels in patients with chronic kidney disease combined with subclinical hypothyroidism under the influence of combined antihypertensive therapy]. Medicni perspektivi. 2018;23(2 part 1):19-25. Ukrainian.
Кushnir JS. [Hemodynamics, functional state of the endothelium, kidneys and platelets depending on the body mass index in patients with chronic heart failure with preserved systolic function]. Medicni perspektivi. 2014;19(1):29-36. Ukrainian.
Cooper D, Biondi B. Subclinical thyroid disease. Lancet. 2012;379(9821):1142-54.
Hylander В, Ekelund LG, Rosenqvist U. The cardiovascular response at rest and during exercise in hypothyroid subjects to thyroxine substitution Clin. Cardiol. 2013;3:116-24.
Ivanov DD, Kuryata OV, Garmish IP. Renin angiotensin-aldosteron system blockers: chronic kidney disease and cardiovascular risk. Kidneys. 2018;2:13-22
Chongol M, Lippi G, Salvagno G, Zoppini G, Michele M, Giovanni T. Prevalence of Subclinical hypothyroidism in patients with chronic kidney disease Clin J Am Soc Nephrol. 2008;3(5):1296-300.
Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur. Heart J. 2013;35(19):1245-54.
##submission.downloads##
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2018 Медичні перспективи
Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.